NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the fourth quarter fell 31 percent year over year, but the company still beat the average Wall Street estimate on the top and bottom lines.

The Carlsbad, Calif.-based molecular diagnostics firm reported $6.5 million in total revenues for the three months ended Dec. 31, 2013, compared to $9.4 million in the year-ago fourth quarter and besting the consensus Wall Street estimate of $6.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.